NewsRoom Articles

FridayApr 10, 2026 11:15 am

Frontieras North America Inc. Unlocks Value in America’s Energy Future

Frontieras is developing breakthrough technologies that convert abundant solid hydrocarbons such as coal into cleaner fuels, hydrogen and industrial energy products. Central to this strategy is the company’s patented FASForm(TM) Solid Carbon Fractionation process. The company has not only developed its technology but is moving toward commercialization. Frontieras North America is emerging as a noteworthy innovator and attractive potential investment opportunity by addressing one of the most critical challenges facing modern technology: the rapidly growing demand for reliable, affordable electricity. As artificial intelligence (“AI”) and data-intensive computing expand, global electricity demand is projected to soar, with some analysts estimating AI-related…

FridayApr 10, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers The company’s acquisition of Liora Technologies introduces a complementary therapy platform with recurring revenue potential These updates underscore LIXTE’s broader strategy: integrating drug development and med-tech innovation to redefine cancer treatment LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical…

FridayApr 10, 2026 9:00 am

Rail Vision Ltd. (NASDAQ: RVSN) Positions AI-Powered Collision Avoidance Tech as Solution to Rail Safety Mandates

The National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple rail incidents. Rail Vision’s proprietary sensor systems are designed to address key railway safety challenges by combining advanced imaging technologies with artificial intelligence and deep learning algorithms. The company’s technology is also designed to integrate with existing rail infrastructure, providing flexibility for operators seeking to upgrade safety capabilities without requiring extensive system overhauls. Rail-safety regulators are increasingly calling for advanced collision-avoidance systems as rail networks grow more complex, and Rail Vision’s (NASDAQ: RVSN, FSE: C80) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological…

ThursdayApr 09, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The company recently strengthened its position through a strategic partnership with Liora Technologies and the expansion of clinical trials These developments highlight Lixte’s broader mission: To improve cancer outcomes through innovation, combination-based therapeutic strategies Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its…

WednesdayApr 08, 2026 10:00 am

Block Co-Founder Foresees AI Doing Middle Management Tasks

Jack Dorsey is making a concrete bet that artificial intelligence can replace what middle managers have done in large organizations for generations. Block’s chief executive, writing jointly with lead independent director Roelof Botha, has outlined a structural transformation in which AI takes on work currently handled by layers of human management. That means moving information, tracking progress and generating real-time operational visibility across the entire business, without a manager in the middle. The case they make starts with a critique of hierarchy itself. Management layers were designed to solve an information problem. In large organizations, someone has to gather data, relay it upward and translate decisions back down. Dorsey and Botha believe…

WednesdayApr 01, 2026 10:00 am

Researchers Solve 50-Year-Old Challenge in Making Cancer Drug

Scientists have overcome production barriers that have plagued doxorubicin manufacturing since the 1970s by engineering bacteria that generate 180% more of the critical chemotherapy drug than current methods achieve. The breakthrough addresses molecular bottlenecks that forced pharmaceutical companies to rely on expensive, multi-step processes despite treating over one million cancer patients annually with the medication. The advance could reshape how essential medicines get produced globally. Doxorubicin has been essential to the treatment of breast cancer, bladder cancer, lymphomas, and carcinomas since gaining approval five decades ago. However, bacteria that naturally synthesize the compound do so extremely inefficiently, creating supply constraints…

TuesdayMar 31, 2026 11:15 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far. LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.…

MondayMar 30, 2026 10:00 am

Research Suggests the Thymus is Critical in Immunotherapy Outcomes

Cancer patients with healthier thymus glands show dramatically better responses to immunotherapy, cutting progression risks by roughly one-third and death risks by nearly half compared to those with weaker thymic function. New research leveraging artificial intelligence to evaluate chest scans challenges medical assumptions that dismissed this immune organ as irrelevant past childhood, revealing it may determine who benefits from modern cancer treatments that are dependent on robust immune systems. Separate research tracking over 27,000 adults found those with stronger thymic function lived longer while experiencing half the premature mortality, one-third fewer cardiovascular deaths, and substantially reduced lung cancer development versus people showing poorer thymic health on imaging. Hugo Aerts from Harvard Medical School and Dana-Farber Cancer Institute,…

MondayMar 30, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments. The company recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study. Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need…

ThursdayMar 26, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials These developments position the company at the intersection of innovation and therapeutics Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000